A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

This early-phase trial is testing a new drug called Af-001 in people with differentiated thyroid cancer (a type including papillary and follicular thyroid cancer) that has come back or spread and is no longer responding to standard treatments. **You may be eligible if...** - You have papillary or follicular thyroid cancer that has been fully removed surgically - Your cancer has come back or spread and cannot be surgically removed - Your cancer is either resistant to or no longer a candidate for standard therapy (Part Ia), OR your cancer has not yet been treated with radioactive iodine (Part Ib) - You have at least one measurable tumor lesion - Your general health is reasonable (ECOG 0–2) and you are expected to survive at least 6 more months **You may NOT be eligible if...** - You have a thyroid cancer type other than papillary or follicular - Your cancer has not relapsed or spread - Your organ function is significantly impaired Talk to your doctor to see if this trial is right for you.